First Time Loading...

ATAI Life Sciences NV
NASDAQ:ATAI

Watchlist Manager
ATAI Life Sciences NV Logo
ATAI Life Sciences NV
NASDAQ:ATAI
Watchlist
Price: 2.02 USD 5.76% Market Closed
Updated: May 15, 2024

Profitability Summary

ATAI Life Sciences NV's profitability score is 25/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

25/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

25/100
Profitability
Score
25/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
ATAI Life Sciences NV

Revenue
314k USD
Operating Expenses
-125.8m USD
Operating Income
-125.5m USD
Other Expenses
85.2m USD
Net Income
-40.2m USD

Margins Comparison
ATAI Life Sciences NV Competitors

Country Company Market Cap Operating
Margin
Net
Margin
DE
ATAI Life Sciences NV
NASDAQ:ATAI
335.4m USD
-39 959%
-12 810%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
-79%
US
Eli Lilly and Co
NYSE:LLY
744.4B USD
32%
17%
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK
45%
37%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
367.4B USD
28%
45%
US
Merck & Co Inc
NYSE:MRK
333.6B USD
10%
4%
UK
AstraZeneca PLC
LSE:AZN
188.7B GBP
18%
13%
CH
Novartis AG
SIX:NOVN
182.5B CHF
28%
30%
CH
Roche Holding AG
SIX:ROG
181.4B CHF
32%
20%
US
Pfizer Inc
NYSE:PFE
162.7B USD
19%
-1%
Country DE
Market Cap 335.4m USD
Operating Margin
-39 959%
Net Margin
-12 810%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Net Margin
-79%
Country US
Market Cap 744.4B USD
Operating Margin
32%
Net Margin
17%
Country DK
Market Cap 4.1T DKK
Operating Margin
45%
Net Margin
37%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Net Margin
-4%
Country US
Market Cap 367.4B USD
Operating Margin
28%
Net Margin
45%
Country US
Market Cap 333.6B USD
Operating Margin
10%
Net Margin
4%
Country UK
Market Cap 188.7B GBP
Operating Margin
18%
Net Margin
13%
Country CH
Market Cap 182.5B CHF
Operating Margin
28%
Net Margin
30%
Country CH
Market Cap 181.4B CHF
Operating Margin
32%
Net Margin
20%
Country US
Market Cap 162.7B USD
Operating Margin
19%
Net Margin
-1%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
ATAI Life Sciences NV Competitors

Country Company Market Cap ROE ROA ROCE ROIC
DE
ATAI Life Sciences NV
NASDAQ:ATAI
335.4m USD
-16%
-13%
-45%
-185%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-441%
-47%
-108%
-64%
US
Eli Lilly and Co
NYSE:LLY
744.4B USD
51%
10%
28%
17%
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK
100%
33%
87%
36%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
367.4B USD
52%
21%
19%
14%
US
Merck & Co Inc
NYSE:MRK
333.6B USD
5%
2%
7%
4%
UK
AstraZeneca PLC
LSE:AZN
188.7B GBP
17%
6%
12%
10%
CH
Novartis AG
SIX:NOVN
182.5B CHF
38%
17%
22%
17%
CH
Roche Holding AG
SIX:ROG
181.4B CHF
40%
13%
29%
22%
US
Pfizer Inc
NYSE:PFE
162.7B USD
0%
0%
6%
1%
Country DE
Market Cap 335.4m USD
ROE
-16%
ROA
-13%
ROCE
-45%
ROIC
-185%
Country JP
Market Cap 776 550.9T JPY
ROE
-441%
ROA
-47%
ROCE
-108%
ROIC
-64%
Country US
Market Cap 744.4B USD
ROE
51%
ROA
10%
ROCE
28%
ROIC
17%
Country DK
Market Cap 4.1T DKK
ROE
100%
ROA
33%
ROCE
87%
ROIC
36%
Country UK
Market Cap 440.4B GBP
ROE
-4%
ROA
-2%
ROCE
2%
ROIC
2%
Country US
Market Cap 367.4B USD
ROE
52%
ROA
21%
ROCE
19%
ROIC
14%
Country US
Market Cap 333.6B USD
ROE
5%
ROA
2%
ROCE
7%
ROIC
4%
Country UK
Market Cap 188.7B GBP
ROE
17%
ROA
6%
ROCE
12%
ROIC
10%
Country CH
Market Cap 182.5B CHF
ROE
38%
ROA
17%
ROCE
22%
ROIC
17%
Country CH
Market Cap 181.4B CHF
ROE
40%
ROA
13%
ROCE
29%
ROIC
22%
Country US
Market Cap 162.7B USD
ROE
0%
ROA
0%
ROCE
6%
ROIC
1%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More